* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies. 

 

Our multifunctional nano-technology carrier platform harnesses the physical (magnetic, electromagnetic and acoustic)and chemical properties of graphene to generate a diversified product pipeline for diagnostic, therapeutic and regenerative medicine. Graphene's properties "actively" enhances the overall attributes of the constructs rather than serving as a passive carrier.

 

 

Fundamental Attributes of Our Platforms:

 

  • Versatile carrier or scaffold for variety of medical interesting atoms and molecules. 

  • Allows multi-modal clinical and molecular imaging over various length and time scales.

  • Facilates stimulus responsive therapeutics and tissue engineering. 

 

 

ManGraDex

PLATFORM VALUE PROPOSITION:

  • Modular platform for multimodal clinical and molecular imaging.

  • Detectable by magnetic resonance, photoacoustic, and Raman imaging.

  • Suitable for whole body screening of vital organs or vascular imaging.

  • Could facilitate improved image-guided pre-operative staging and intraoperative procedures (e.g. cancer staging and resection).

 

CURRENT STATUS:

  • Conducting investigational new drug (IND)- enabling preclinical studies to assess its efficacy as a long circulating MRI contrast agent for unserved and underserved renal and cardiovascular patient population. 

  • Conducting preclinical studies to assess its efficacy  for photoacoustic imaging of sentinel lymph nodes for breast cancer.

  • Conducting preclinical studies to assess its efficacy for molecular breast cancer screening by MRI (significantly improved specificity).

Nano-GenXb

PLATFORM VALUE PROPOSITION:

  • Modular platform for image-guided drug and gene delivery.

  • Promotes multivalent ligand−cell receptor interactions for enhanced delivery.

  • Allows increased drug or gene-loading capacity.

  • Facilitates stimulus-responsive controlled drug or gene release inside target cells.

  • Enables real-time tracking by multimodal imaging systems.

 

CURRENT STATUS:

  • Completed non-GLP safety pharmacology studies in small animals.

  • Scale up and GLP manufacturing in progress.

  • GLP safety pharmacology studies planned in first quarter of 2017.

  • Conducting preclinical efficacy studies for image-guided delivery of drugs for human papiloma virus (HPV)-induced head and neck cancer.

COLLABORATORS:

  • Dr. John Haley and Dr. Kenneth Shroyer, Stony Brook University
    Conducting preclinical efficacy studies for image-guided delivery of CRISPR/Cas9 constructs to treat Herpesvirus infections.

  • Dr. Laurie Krug, Stony Brook University
    Conducting preclinical efficacy studies for image-guided delivery of
    microRNAs to treat breast cancer metastases.

  • Dr. Vivek Mittal, Weill Cornell and Mircan Therapeutics 
    Conducting preclinical efficacy studies for image-guided delivery of myelin

      basic protein nucleic acid therapeutics to treat Alzheimer’s disease.

  • Dr. William Van Nostrond, Stony Brook University and Gyrus Pharmaceuticals

GraFix

PLATFORM VALUE PROPOSITION:

  • Modular three dimensional all carbon implantable graft substitute (porous scaffold) for tissue engineering.

  • Generates biophysical stimulus, rather than biochemical cue to affect the differentiation of stem cells.

  • Facilitates controlled release of biologics into the regenerating tissue.

  • Allows real time monitoring of anatomical and physiological changes during the tissue regeneration process by multimodal imaging.

 

CURRENT STATUS:

  • Conducting preclinical studies to assess its safety and efficacy as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in open fractures. 

  • Conducting preclinical studies to assess its safety and efficacy as a as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in burn wounds. 

Our Platform Technology